Listen and follow our podcasts on:

This educational programme is supported by an Independent Medical Education Grant from Viatris.

In this second podcast episode of a 4-part series, haematologists continue to explore different clinical scenarios and challenges in managing thrombosis.

In this conversation, they discuss how to treat thrombosis in patients with cancer, covering:

 

  • When and how to use heparins and/or direct oral anticoagulants (DOACs)

  • The benefits of primary thromboprophylaxis and its efficacy in various tumour types

  • How the patient's involvement could result in an improved quality of life

 

E-learning

After listening to the podcast series, take the e-learning assessment to test your knowledge and earn CME credits.

 

Clinical takeaways

 

  • Heparins and/or DOACs are safe and efficient in treating thrombosis in cancer patients

  • Primary thromboprophylaxis is efficient in selected cancer patients but still remains a matter of debate for the majority of tumours

  • To improve quality of life, it is important to involve the patient in the treatment decision-making process

Prof. Dimitrios A. Tsakiris, MD was born in Thessaloniki, Greece and obtained his Diploma of Medicine (1982) at the Medical School, Aristotle University of Thessaloniki, Greece. He started his training in Clinical Haematology at the AHEPA University Hospital in Thessaloniki and completed it at the University Hospital Basel in Basel, Switzerland, where he has been working since 1987. He holds a license for Clinical Haematology and Laboratory Haematology. He spent one year (1996) as a Research Associate in Platelet Research at the Mount Sinai School of Medicine, New York, NY, USA. He has held a professorship in Haematology at the Faculty of Medicine, University of Basel, Switzerland since 2004 and serves also as a visiting Professor of Hematology at the Medical School of the Aristotle University of Thessaloniki. He has served as Head of Haemostasis since 2009 and Head of Diagnostic Haematology and Haemostasis (2014-2021), as well as member of the Stem Cell Transplant and Cell-Therapy Center Basel at the University Hospital Basel, Switzerland. Since 2021 he has been Director of Thrombosis and Haemostasis and Co-Head Hematology at SYNLAB Suisse SA, Switzerland. His main fields of scientific interests are platelet activation, platelet disorders, diagnosis and treatment of bleeding disorders and thrombophilia, disorders of haemostasis and endothelial cells after stem cell transplants. He has presented over 140 peer-reviewed original articles and reviews.

Dr Lars Asmis is Director at the Centre for Perioperative Thrombosis and Haemostasis in Zurich, Switzerland.  He completed his medical training at the University of Bern and has subsequently held positions at Inselspital Bern, University of Geneva and USZ Zurich.  In 2002 he worked as a visiting scientist at Johns Hopkins University in Baltimore, USA.  Dr Asmis has held a number of leadership positions including Co-president of the Swiss Working Party for Hemostasis from 2020 to 2021.  He has authored more than 50 peer-reviewed publications.

Dr Lars Asmis has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Viatris

Programme summary
Listen to the podcast now
Other episodes in this series
Monitoring Anticoagulation: Yes or No?

Monitoring Anticoagulation: Yes or No?

A clinical discussion on anticoagulation monitoring

Cancer and Thrombosis

Cancer and Thrombosis

A podcast discussion on treating thrombosis in patients with cancer

Current Episode
VTE: What is the optimal duration of antithrombotic treatment?

VTE: What is the optimal duration of antithrombotic treatment?

Part 3 of a 4-part series on thrombosis

Perioperative thromboprophylaxis revisited

Perioperative thromboprophylaxis revisited

Minimising the risk of thrombosis in surgical patients

Share this programme
This educational programme is supported by an Independent Medical Education Grant from Viatris.
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
HEMOSTASIS CONNECT

HEMOSTASIS CONNECT is an initiative of COR2ED, supported by Independent Medical Educational Grants from Pfizer, Takeda, Viatris and Pentapharm.

Meet the experts

Other programmes of interest

Other
Oncology 
The evolving role of liquid biopsy in biomarker testing

Clinical application of liquid biopsy, and how it applies to NSCLC, breast and colorectal cancer

Experts
Assoc. Prof. Umberto Malapelle
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Interactive patient case
Oncology 
Advanced renal cell carcinoma: Managing a long-term durable response

Maximising outcomes for patients with advanced RCC 

Experts
Prof. Michael Staehler
Endorsed by
Urobel VZW | ASBL
  • clock 15 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Eisai Europe Limited.
Other

Episode

1

of 1

episode
Oncology 
Overcoming pre-analytical phase challenges in gastric, prostate and lung cancer

Medical experts make recommendations for best practice

Experts
Dr Alexander Wyatt, Prof. Frédéric Bibeau
Endorsed by
AMP
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from AstraZeneca and Amoy Diagnostics.
Conference update
Oncology 
Oncogene-addicted NSCLC: Highlights from ASCO 2024

The latest non-small cell lung cancer data presented at ASCO

Experts
Prof. Nicolas Girard
  • download Downloadable
    Resources
  • clock 3 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Upper lower GI cancer update ASCO 2024 Conference update
Oncology 
Upper and lower GI cancer update from ASCO 2024

GI oncologists review the latest data presented at ASCO 2024

Experts
Dr Samuel J Klempner, Dr Elizabeth Smyth, Prof. Jenny Seligmann, Dr Dominik Modest
  • clock 8 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Bayer.
Experts Knowledge Share Video
Oncology Hemato-oncology 
Optimising the management of multiple myeloma in the early relapsed/refractory setting (RRMM)

Medical experts discuss the latest learnings from clinical practice

Experts
Prof. Aurore Perrot, Prof. Hermann Einsele, Assoc. Prof. Karthik Ramasamy, Assoc. Prof. Joshua Richter
  • download Downloadable
    Resources
  • clock 76 MIN
  • calendar Jun 2024

Educational programme supported by an Independent Medical Education grant from Menarini Stemline Oncology.